Juan Wisnivesky, MD, DrPH Email Juan Wisnivesky
-
- Position
- PROFESSOR | Medicine, General Internal Medicine
-
- Specialty
- Pulmonary Medicine (Lung)
-
- Language
- English
-
- Hospital Affiliation
- The Mount Sinai Hospital
He received a K award from the Agency for Healthcare Research and Quality (AHRQ) to identify determinants of medication adherence and outcomes among inner-city asthmatics and a grant funded by the New York State Department of Health to assess the management of minority asthmatics. He has also been involved in several inpatient, outpatient and physician studies assessing the treatment and outcomes of inner-city asthmatics. He is also the PI of an R01 grant evaluating self-management of patients with chronic obstructive pulmonary disease. He was the PI of an R03 grant to validate a pulmonary tuberculosis prediction rule.
News
Mount Sinai Study Shows that Language Barriers may Interfere with the Care of Asthma Patients.
Find out more here
Dr. Juan Wisnivesky discusses lung cancer risks in The Daily News feature The Daily Check Up.
Certification
Pulmonary Disease
Education
MD, University of Buenos Aires
MD, University of Buenos Aires, Argentina
MPH, Columbia University
DrPH, Columbia University
Residency, Internal Medicine
Montefiore Medical Center
Fellowship, Pulmonary & Critical Care
New York-Presbyterian Medical Ctr.
Language
English
2010
Research Excellence Award
Department of Medicine, MSSM
2009
Joseph L. Fleiss Prize Biostatistics , Columbia University
1998
Young Investigator Award
CHEST
1998
J. Burns Amberson Fellow
American Lung Association of New York
1996
Outstanding House Officer Award
Montefiore Medical Center, Albert Einstein College of Medicine
1990
Cum Laude
University of Buenos Aires School of Medicine
Research interests include:
Asthma, lung cancer screening, Tuberculosis. Please visit the Wisnivesky Laboratory.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Wisnivesky during 2021 and/or 2022. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Atea
- Banook
- banook
- sanofi-aventis
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Merus Pharmaceutical
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- banook
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.